- Home
- IRON vs NWN Comparison
IRON vs NWN Comparison
Compare IRON & NWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- NWN
- Stock Information
- Founded
- IRON 2017
- NWN 1859
- Country
- IRON United States
- NWN United States
- Employees
- IRON N/A
- NWN N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- NWN Oil/Gas Transmission
- Sector
- IRON Health Care
- NWN Utilities
- Exchange
- IRON Nasdaq
- NWN Nasdaq
- Market Cap
- IRON 1.8B
- NWN 1.6B
- IPO Year
- IRON N/A
- NWN N/A
- Fundamental
- Price
- IRON $55.86
- NWN $41.44
- Analyst Decision
- IRON Strong Buy
- NWN Strong Buy
- Analyst Count
- IRON 11
- NWN 3
- Target Price
- IRON $92.64
- NWN $46.33
- AVG Volume (30 Days)
- IRON 390.2K
- NWN 366.9K
- Earning Date
- IRON 08-07-2025
- NWN 08-01-2025
- Dividend Yield
- IRON N/A
- NWN 4.73%
- EPS Growth
- IRON N/A
- NWN 11.40
- EPS
- IRON N/A
- NWN 2.61
- Revenue
- IRON N/A
- NWN $1,213,808,000.00
- Revenue This Year
- IRON N/A
- NWN $16.91
- Revenue Next Year
- IRON N/A
- NWN $6.75
- P/E Ratio
- IRON N/A
- NWN $15.89
- Revenue Growth
- IRON N/A
- NWN 3.88
- 52 Week Low
- IRON $30.82
- NWN $35.11
- 52 Week High
- IRON $68.73
- NWN $44.38
- Technical
- Relative Strength Index (RSI)
- IRON 61.10
- NWN 58.23
- Support Level
- IRON $52.70
- NWN $40.38
- Resistance Level
- IRON $55.26
- NWN $41.74
- Average True Range (ATR)
- IRON 2.42
- NWN 0.78
- MACD
- IRON 0.01
- NWN 0.21
- Stochastic Oscillator
- IRON 92.71
- NWN 87.60
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company operates in one reportable business segment, which is NW Natural's local gas distribution business and is referred to as the NGD segment. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.